On the fly News and insights, exclusive to thefly.com

FTSV

Forty Seven

$48.78 /

+0.28 (+0.58%)

17:37
02/27/20
02/27
17:37
02/27/20
17:37

Forty Seven jumps 23% after Bloomberg report of Gilead approach

Forty Seven (FTSV), a clinical-stage immuno-oncology company, is higher by over 23% in after-hours trading following a report by Bloomberg's Ed Hammond and Nabila Ahmed that Gilead Sciences (GILD) has approached the company with a takeover offer, and that the companies have also discussed other options, including a partnership. The report also added that Forty Seven has "received interest from other potential suitors as well," citing their source. In after-hours trading, Forty Seven is up 23.4% to $60.20, while Gilead is higher by 1.5% to $73.76.

  • 02

    Mar

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.